Trial | NCT00870025  Report issue

Title

Human Chorionic Gonadotropin (hCG) Priming Prior to Controlled Ovarian Hyperstimulation (COH) in Poor Responder In Vitro Fertilization (IVF) Patients
hCG Priming Prior to COH in Poor Responder IVF Patients

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    60
There is a decline in androgen concentration with ovarian aging. Also, ovarian response to COH in IVF cycles diminishes with ovarian aging. Recent evidence suggest that testosterone or DHEA may improve ovarian response in poor prognosis patients by increasing intraovarian androgen concentration. A physiological way to induce androgen synthesis within the ovary is to stimulate theca cells androgen production by hCG stimulation. By doing this in the previous cycle we might expect a better response to COH.
Study Started
Oct 31
2008
Primary Completion
Sep 30
2010
Study Completion
Sep 30
2010
Last Update
Apr 22
2015
Estimate

Biological human chorionic gonadotropin

200 IU, sc, every 5 days, 4 doses

Biological placebo

diluent, every 5 days, s.c., 4 doses

hCG Active Comparator

200 IU rec hCG s.c./5 days, 4 doses prior to onset of COH

placebo Placebo Comparator

similar injection at same time points with similar diluent but no hCG

Criteria 

Inclusion Criteria:

previous IVF cycle with 5 or less mature follicles or 5 or less oocyte retrieved

Exclusion Criteria:

42 years or older
BMI <18 or >30
No Results Posted